key: cord-0688384-2shqq5ph
authors: Murrell, Dedee F.; Lucky, Anne W.; Salas-Alanis, Julio C.; Woodley, David T.; Palisson, Francis; Natsuga, Ken; Nikolic, Milos; Ramirez-Quizon, Mae; Paller, Amy S.; Lara-Corrales, Irene; Barzegar, Mohammadreza Amir; Sprecher, Eli; Has, Cristina; Laimer, Martin; Bruckner, Anna L.; Bilgic, Asli; Nanda, Arti; Purvis, Diana; Hovnanian, Alain; Murat-Sušić, Slobodna; Bauer, Johannes; Kern, Johannes S.; Bodemer, Christine; Martin, Linda K.; Mellerio, Jemima; Kowaleski, Cezary; Robertson, Susan J.; Bruckner-Tuderman, Leena; Pope, Elena; Marinkovich, M Peter; Tang, Jean Y.; Su, John; Uitto, Jouni; Eichenfield, Lawrence F.; Teng, Joyce; Aan Koh, Mark Jean; Lee, Sang Eun; Khuu, Phuong; Rishel, Heather I.; Sommerlund, Mette; Wiss, Karen; Hsu, Chao-Kai; Chiu, Tor Wo; Martinez, Anna E.
title: Multidisciplinary Care of Epidermolysis Bullosa during the COVID-19 Pandemic – Consensus: Recommendations by an International Panel of Experts
date: 2020-07-16
journal: J Am Acad Dermatol
DOI: 10.1016/j.jaad.2020.06.1023
sha: 5b59250cd0f2ae83570704bae3f369021b37fc6a
doc_id: 688384
cord_uid: 2shqq5ph

nan

The 2019 novel coronavirus' (COVID-19) pandemic became apparent in China during the International Congress on Epidermolysis Bullosa, (EB) in London, in January 2020. Many EB patients have medical problems that make them a vulnerable population of patients. 1 Herein, we developed an international consensus to suggest best management of EB patients during the pandemic.

The SARS-CoV-2 virus enters host cells using its spike protein binding to the cell receptor Angiotensin Converting Enzyme 2 (ACE2), which is expressed in several tissues. Mucosae have high ACE2 expression, particularly the nasal epithelium. ACE2 is also expressed in the basal layer of keratinocytes and sebaceous glands of normal skin, as well as in vascular endothelial cells, but its expression in wounded EB skin has not been studied. 2 A questionnaire was drafted by DM into a table of suggested modifications to the management of EB during the COVID-19 pandemic. Fifty seven well-known experts on EB were selected based on membership of the international Clin-et group and/or clinical expertise in EB demonstrated at International EB Congress participation. Responses and reasons for each response were requested individually to the lead author based on an ideal scenario, rather than what actually may happen in some centers with financial constraints. A priori, consensus was considered to be the agreement of more than 70% of respondents with the suggestion. Questionnaires were returned by 44 of the 57 EB experts, representing several areas of clinical expertise in EB (dermatology, pediatrics, internal medicine and surgery) from 5 continents. After addition and revision of some items and 3 cycles of revoting, consensus was achieved for all items, which are summarized in Supplementary Table 1 (doi:10.17632/zmpncb6zpr.1 ).

The main change in usual practice was the introduction of photographs from the patient/family and teledermatology as the primary visit for the less severe EB patients, with dressing supplies sent to the patients directly. For those EB patients with significant internal disease, monitoring tests (blood and urine) must continue, but can be obtained by local laboratories or family doctors close to home. 3 If telehealth images are insufficient to assess lesions, assessments should be conducted at the EB center. 4 One of the greatest fears of families caring for patients with severe forms of EB is how they will be perceived on admission to hospitals, especially institutions with limited resources, including ventilators. As EB patients often appear frail and emaciated, healthcare workers unfamiliar with the condition may underestimate their resilience and incorrectly assume that they have a low likelihood of survival.. 5 If an EB patient required anticoagulation to manage COVID-19, there might be additional bleeding from the skin or mucosae, but blood transfusions will compensate for this. The Table details protection for the skin and mucosae that is required for wearing masks and ventilation.

Yours sincerely, Dedee F Murrell, BMBCh MD FRCP, a Anne W. Lucky, MD, b Julio C. Salas-Alanis MD

Consensus re-classification of epidermolysis bullosa and other disorders with skin fragility

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

Management of Epidermolysis Bullosa Exp Opin Orph Drugs

Management of cutaneous squamous cell carcinoma in patients with epidermolysis bullosa -best clinical practice guidelines

The challenges of living with and managing epidermolysis bullosa: insights from patients and caregivers